Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.27)
# 4,305
Out of 5,005 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $40.86 | +17.47% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $15.02 | +99.80% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $86.85 | -10.19% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $21.65 | +84.76% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $2.05 | +1,021.95% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $40.86
Upside: +17.47%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $15.02
Upside: +99.80%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $86.85
Upside: -10.19%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $21.65
Upside: +84.76%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $2.05
Upside: +1,021.95%